Pragma Pharmaceuticals announced the relaunch of Moxatag (amoxicillin extended-release tablets), 775 mg.
Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.
The Food and Drug Administration has announced approval for Belsomra (suvorexant) tablets, which are used to treat insomnia.
Tummy Co. recently launched a fast-acting liquid antacid in a shot format called Relief OTC, the company announced Wednesday.
Sanofi on Tuesday announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop U.S., the company’s generics division.
Janssen Pharmaceuticals received approval from the Food and Drug Administration for Invokamet, a fixed-dose therapy that combines canagliflozin and metformin hydrochloride in a single tablet.
Mylan announced the launch of capecitabine tablets USP in 150-mg and 500-mg dosage strengths, a generic version of Xeloda tablets from Genentech.
The Food and Drug Administration earlier this week announced approval for Orbactiv (oritavancin), an antibacterial drug used to treat patients with acute bacterial skin and skin structure infections.
The BBC on Tuesday reported that a team has developed an app and small lens add-on that allows blood-cell analysis via a smartphone.
Lannett Co. on Monday announced that its abbreviated new drug application for oxycodone hydrochloride capsules, 5 mg, has been approved by the Food and Drug Administration.